ZTS Zoetis
Zoetis is a mature but dominant animal-health franchise, priced near fair value after the rebound.
The story
Zoetis is the global leader in animal health, with a broad portfolio across companion animals and livestock, strong vet relationships, and pricing power from products that pet owners rarely trade down from. It is a mature franchise: growth has slowed as pet ownership normalizes after the pandemic and competitors push into dermatology and parasiticides, but its scale, R&D pipeline, and diversified portfolio still produce high, durable margins and strong cash flow.
No material facts have changed since 2026-09-30. TTM revenue of 9.52B and a 36.9% margin are in line with the slow-growth, high-margin story, so I'm keeping every driver. The target margin stays slightly below the current 37% to allow for competitive pressure on key franchises (Apoquel/Cytopoint, Simparica), and the 7-year horizon reflects a mature leader rather than a long-runway compounder.
Value drivers
| Revenue growth (Y1) | 3.5% |
| Terminal growth | 3.0% |
| Forecast horizon | 7y |
| Target operating margin | 35.0% |
| Years to target margin | 5 |
| Sales-to-capital | 0.77 |
| Beta | 1.00 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.5% |
| Terminal WACC | 8.5% |
Valuation bridge
| PV of explicit FCFF | 13.33B |
| PV of terminal value | 27.83B |
| Equity value | 33.75B |
| ÷ shares → per share | $81.67 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 9.85B | 3.5% | 36.5% | 2.86B | 432.59M | 2.43B | 2.24B |
| 2 | 10.19B | 3.4% | 36.1% | 2.93B | 437.07M | 2.49B | 2.12B |
| 3 | 10.53B | 3.3% | 35.8% | 2.99B | 440.98M | 2.55B | 2.00B |
| 4 | 10.87B | 3.2% | 35.4% | 3.06B | 444.29M | 2.61B | 1.89B |
| 5 | 11.21B | 3.2% | 35.0% | 3.12B | 446.96M | 2.68B | 1.78B |
| 6 | 11.56B | 3.1% | 35.0% | 3.22B | 448.98M | 2.77B | 1.70B |
| 7 | 11.90B | 3.0% | 35.0% | 3.31B | 450.32M | 2.86B | 1.62B |
Key risks
- Competitive entrants and biosimilars eroding dermatology and parasiticide franchises
- Safety concerns or slower uptake of the Librela/Solensia osteoarthritis pain franchise
- Slowing vet visit volumes and pressure on pet owners' spending
Catalysts
- New product launches and label expansions that revive companion-animal growth
- Capital returns (buybacks) at depressed multiples, plus steady margin delivery